The short version
- What the evidence isIts own 2025 review states that human studies are limited and that no clinical trial following international standards is available (Jedrejko 2025).
- What to watchOverheating, flushing or sweating beyond what you expect, if mitochondrial coupling is really being shifted.
How Hypoxen works
A polymeric phenolic thiosulfonate sodium salt. The 2025 review lists three proposed actions: improved coupling in the respiratory chain with accelerated oxidative phosphorylation, inhibition of succinate dehydrogenase, and activation of mitochondrial ATP-sensitive potassium channels in skeletal muscle and myocardium. The first and third pull in opposite directions, so the mechanism as published is a list rather than a chain. The succinate dehydrogenase claim is the interesting one: blocking succinate oxidation at complex II is the strategy the reperfusion literature identifies as protective — and it is the exact opposite of what Cytoflavin, sold on the same shelf, is designed to do.
The one modern review of this compound says two things at once, and both are the page. Jedrejko 2025 is a 2025 review in an anti-doping journal.
The proposed mechanism contains an internal tension worth naming. The same review lists three actions: improved coupling in the respiratory chain with accelerated oxidative phosphorylation, inhibition of succinate dehydrogenase, and activation of mitochondrial ATP-sensitive potassium channels in skeletal muscle and myocardium Jedrejko 2025. Improved coupling and mitoKATP activation pull in opposite directions — opening that channel depolarizes the inner membrane slightly, which is the opposite of tighter coupling.
- Oral
On the goal map: Exercise mimetics & mitochondrial biogenesis (Endurance & work capacity)
Research on Hypoxen7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Its own 2025 review states that human studies are limited and that no clinical trial to international standards is available. WADA added it to the Monitoring Program in 2023.
Human clinical evidence
Its own 2025 review states that human studies are limited and that no clinical trial following international standards is available (Jedrejko 2025). What exists instead is described as a developed body of work from Russia's military medical research establishment in the 1980s and 1990s, with limited online access — a literature nobody outside can read, check or cite.
WADA added it to the Monitoring Program in 2023 after documented evidence of use by athletes. The same review names performance enhancement as the first criterion considered for adding a substance to the Prohibited List, and concludes only that the studies may provide some evidence of potential.
Correlative data
Reviewed with Mexidol and the succinate derivatives as an antihypoxic, anti-ischemic metabolic modulator used as an ergogenic aid (Jedrejko 2024), inside a wider pharmacology of targeting mitochondrial dysfunction in cerebral ischemia (Belenichev 2025).
No pharmacokinetic parameter has ever been published — no bioavailability, no time to peak, no half-life, no clearance route. For a substance on an anti-doping monitoring program that is a practical problem too: a detection window is derived from a half-life.
How the mechanism reads
The proposed mechanism is a list rather than a chain: improved respiratory-chain coupling with accelerated oxidative phosphorylation, inhibition of succinate dehydrogenase, and activation of mitochondrial ATP-sensitive potassium channels. The first and third pull in opposite directions.
MechanisticThe succinate dehydrogenase claim points somewhere respectable: blocking succinate oxidation at complex II is the strategy the reperfusion literature identifies as protective (Chouchani 2014). It also puts this tablet in direct opposition to Cytoflavin, sold on the same shelf, which supplies succinate as fuel for the same enzyme.
MechanisticThe comparator its own reviewers chose was 2,4-dinitrophenol, which WADA prohibited in 2024. That is one in vitro comparison and not a claim of equivalence — but the other member of that family has killed people, and the symptom pattern of an uncoupled metabolism is fast pulse, fast breathing and drenching sweat (Hermetet 2024).
Experimental, animal or cell
Sources
- Jedrejko K, Catlin O, Faiss R, Pokrywka A. A Review of Hypoxen Pharmacology and Potential to Enhance Sports Performance. Drug Testing and Analysis 2025 · PMID 40223246
- Jędrejko K, Catlin O, Stewart T, Muszyńska B. Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs. Drug Testing and Analysis 2024 · PMID 38403950
- Hermetet C, Jourdan M, Baert A, Gheddar L, Ameline A, Kintz P, Bouvet R. Case report: fatal long-term intoxication by 2,4-dinitrophenol and anabolic steroids in a young bodybuilder with muscle dysmorphia. Frontiers in Public Health 2024 · PMID 39659715
- Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord ENJ, Smith AC, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014;515(7527):431-435 · PMID 25383517
- Belenichev I. Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions. Antioxidants (Basel) 2025 · PMID 39857442
Hypoxen safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Sulfite or sulfa allergy, since it is a thiosulfonate sulfur compound.
- Heart or lung disease that already limits oxygen use.
- Liver or kidney disease.
- Pregnancy or under 18, with no controlled human study to international standards.
What’s expected
- Claimed gains in oxygen use and endurance under hypoxia, from respiratory chain coupling.
- Mild stomach upset when swallowed.
- Nothing established, as no trial dataset exists.
Watch for
- Overheating, flushing or sweating beyond what you expect, if mitochondrial coupling is really being shifted.
- A rash or itching, as sulfur-containing polymers can sensitize.
- Unusual fatigue on mild effort.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: liver, kidney and bicarbonate for a compound with no toxicology.
- Cystatin C with eGFR: renal clearance of a polymeric salt is uncharacterized.
- hs-CRP: a flare would signal poor tolerance.
Polymeric phenolic thiosulfonate sodium salt proposed to improve respiratory chain coupling and inhibit succinate dehydrogenase; no controlled human data. PMID 40223246 PMID 38403950
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Hypoxen FAQ3 common questions
- Is Hypoxen approved for human use?
- No. Hypoxen is a research compound.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Cystatin C with eGFR; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Hypoxen: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



